Ion Cotarla

1.6k total citations · 1 hit paper
19 papers, 1.1k citations indexed

About

Ion Cotarla is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ion Cotarla has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Ion Cotarla's work include Lung Cancer Treatments and Mutations (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Ion Cotarla is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Ion Cotarla collaborates with scholars based in United States, Japan and Austria. Ion Cotarla's co-authors include Ramona Dumitrescu, Brian Seal, Apar Kishor Ganti, Engels Chou, Alyssa Klein, Priscilla A. Furth, Shuxun Ren, Edmund A. Gehan, Baljit Singh and Ying Zhang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Ion Cotarla

17 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer in the US

2021 387 citations Apar Kishor Ganti, Alyssa Klein et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ion Cotarla United States	10	563	384	347	183	173	19	1.1k
Chung-Tsen Hsueh United States	19	556 1.0×	416 1.1×	305 0.9×	200 1.1×	82 0.5×	55	1.2k
Ermelinda De Maio Italy	16	533 0.9×	425 1.1×	235 0.7×	284 1.6×	217 1.3×	30	1.1k
Akihiko Suto Japan	15	503 0.9×	285 0.7×	188 0.5×	190 1.0×	260 1.5×	63	945
Davide Lombardi Italy	17	609 1.1×	210 0.5×	308 0.9×	211 1.2×	97 0.6×	57	1.0k
Roberta Maltoni Italy	21	722 1.3×	338 0.9×	299 0.9×	376 2.1×	129 0.7×	84	1.2k
Vincenzo Sforza Italy	18	680 1.2×	380 1.0×	362 1.0×	194 1.1×	84 0.5×	58	1.2k
Sharon B. Sams United States	17	514 0.9×	382 1.0×	208 0.6×	229 1.3×	84 0.5×	40	1.0k
Zakaria Einbeigi Sweden	18	457 0.8×	360 0.9×	189 0.5×	372 2.0×	210 1.2×	54	1.0k
Federica Martorana Italy	14	375 0.7×	326 0.8×	250 0.7×	226 1.2×	85 0.5×	55	869
Teresa Di Desidero Italy	24	542 1.0×	421 1.1×	253 0.7×	200 1.1×	60 0.3×	52	1.1k

Countries citing papers authored by Ion Cotarla

Since Specialization

Citations

This map shows the geographic impact of Ion Cotarla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ion Cotarla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ion Cotarla more than expected).

Fields of papers citing papers by Ion Cotarla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ion Cotarla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ion Cotarla. The network helps show where Ion Cotarla may publish in the future.

Co-authorship network of co-authors of Ion Cotarla

This figure shows the co-authorship network connecting the top 25 collaborators of Ion Cotarla. A scholar is included among the top collaborators of Ion Cotarla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ion Cotarla. Ion Cotarla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Nooruddin, Zohra, Kelly R. Reveles, Jennifer Whitehead, et al.. (2023). Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study. Current Oncology. 30(9). 8411–8423. 4 indexed citations

Nooruddin, Zohra, Kelly R. Reveles, Jim M. Koeller, et al.. (2023). Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration. The Oncologist. 28(9). 804–811. 1 indexed citations

Waterhouse, David, Candice Yong, Tiernan Mulrooney, et al.. (2023). Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting. Future Oncology. 19(28). 1905–1916. 6 indexed citations

Burton, Elizabeth M., Zohra Nooruddin, Ion Cotarla, et al.. (2023). Durvalumab outcomes for patients with PD-L1 positive and negative stage III unresectable non-small cell lung cancer treated at veterans health administration facilities.. Journal of Clinical Oncology. 41(16_suppl). e18793–e18793.

Yong, Candice, et al.. (2022). Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment. SHILAP Revista de lepidopterología. 7 indexed citations

Frei, Christopher R., Kelly R. Reveles, Ion Cotarla, et al.. (2022). Treatment interruptions and discontinuations among patients with stage III unresectable non–small cell lung cancer treated with durvalumab at the Veterans Health Administration.. Journal of Clinical Oncology. 40(16_suppl). 8554–8554.

Ganti, Apar Kishor, Alyssa Klein, Ion Cotarla, Brian Seal, & Engels Chou. (2021). Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer in the US. JAMA Oncology. 7(12). 1824–1824. 387 indexed citations breakdown →

Waterhouse, David, Candice Yong, Nicholas J. Robert, et al.. (2021). Durvalumab consolidation therapy following chemoradiotherapy among patients with unresectable stage III non-small cell lung cancer (NSCLC) treated in a U.S. community oncology network.. Journal of Clinical Oncology. 39(28_suppl). 295–295. 2 indexed citations

Cotarla, Ion, et al.. (2020). Treatment Decision Drivers in Stage III Non–Small-Cell Lung Cancer: Outcomes of a Web-Based Survey of Oncologists in the United States. JCO Oncology Practice. 16(10). e1232–e1242. 13 indexed citations

10.

Pishvaian, Michael J., John L. Marshall, Andrew J. Wagner, et al.. (2012). A phase 1 study of efatutazone, an oral peroxisome proliferator‐activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer. 118(21). 5403–5413. 60 indexed citations

11.

Pishvaian, Michael J., Rebecca Slack, Jan H. Beumer, et al.. (2012). A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy. Cancer Chemotherapy and Pharmacology. 70(6). 843–853. 14 indexed citations

12.

Deeken, John F., Rebecca Slack, Glen J. Weiss, et al.. (2012). A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemotherapy and Pharmacology. 71(3). 627–633. 62 indexed citations

13.

Pishvaian, Michael J., Ion Cotarla, Amy J. Wagner, et al.. (2010). Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies.. Journal of Clinical Oncology. 28(15_suppl). 2526–2526. 5 indexed citations

14.

Pishvaian, Michael J., John L. Marshall, Jimmy J. Hwang, et al.. (2009). A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion. Journal of Clinical Oncology. 27(15_suppl). 3581–3581. 17 indexed citations

15.

Tilli, Maddalena T., Angela R. Parrish, Ion Cotarla, et al.. (2008). Comparison of mouse mammary gland imaging techniques and applications: Reflectance confocal microscopy, GFP Imaging, and ultrasound. BMC Cancer. 8(1). 21–21. 15 indexed citations

16.

Malik, Shakun, Jimmy Hwang, Ion Cotarla, et al.. (2007). P3-112: Initial phase 1 results of gemcitabine, carboplatin and IMO-2055, a toll like receptor 9 (TLR9) agonist, in patients (pts) with advanced solid tumors. Journal of Thoracic Oncology. 2(8). S726–S727. 8 indexed citations

17.

Dumitrescu, Ramona & Ion Cotarla. (2005). Understanding breast cancer risk - where do we stand in 2005?. Journal of Cellular and Molecular Medicine. 9(1). 208–221. 351 indexed citations

18.

Cotarla, Ion, Shuxun Ren, Ying Zhang, et al.. (2003). Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. International Journal of Cancer. 108(5). 665–671. 117 indexed citations

19.

Hruska, Kathleen S., Maddalena T. Tilli, Shuxun Ren, et al.. (2002). Conditional Over-Expression of Estrogen Receptor Alpha in a Transgenic Mouse Model. Transgenic Research. 11(4). 361–372. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact